Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.49 |
| ▸ | MAOA | P21397 | 6/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1710696 | 0.84 | MAOA (0.44) | MAOBMAOALMNACYP3A4ALDH1A1 | |
| SCHEMBL1710628 | 0.79 | SLC6A4 (0.42) | MAOBMAOASLC6A4DAOPPARG | |
| SCHEMBL1710306 | 0.77 | AR (0.42) | MAOBMAOALMNACYP3A4 | |
| SCHEMBL1710887 | 0.77 | LMNA (0.33) | MAOALMNATSHR | |
| SCHEMBL1722194 | 0.75 | LTB4R (0.34) | MAOALMNACYP3A4 | |
| SCHEMBL1710625 | 0.75 | AR (0.41) | — | |
| SCHEMBL1546683 | 0.75 | TSHR (0.52) | LMNATSHRL3MBTL1 | |
| SCHEMBL1546681 | 0.75 | TSHR (0.52) | LMNATSHRL3MBTL1 | |
| SCHEMBL2349389 | 0.75 | TSHR (0.52) | LMNATSHRL3MBTL1 | |
| SCHEMBL1722208 | 0.75 | CTSK (0.33) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102203058-B | Sulfur-linked compounds for the treatment of ophthalmic diseases and disorders | ACUCELA INC | 2014-11-12 | — | — | CN | disclosed |
| CN-102203058-A | Sulfur-linked compounds for the treatment of ophthalmic diseases and disorders | ACUCELA INC | 2011-09-28 | — | — | CN | disclosed |
| EP-2344451-A2 | SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010028088-A2 | SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, MPST, CLN6 | MAOB 2402/4885MAOA 3658/4885SLC6A4 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.